As manufacturing overcapacity reshapes the CGT landscape, success now depends less on access to capacity and more on strategic alignment across development, regulatory readiness, and long-term commercialization.
- The Next Frontier In Women's Cancer Care: Combining Cell Therapy With Immuno-Oncology
- Spine Care Redefined: Autologous Cell Therapy For Degenerative Disc Disease
- A Multi-Agent Audit Intelligence Framework For CDMO Quality Oversight
- Why Contamination Control By Design Should Matter To Your CDMO
- Repeating Sanofi's Ballroom Design On Two Continents
- Early CDMO Engagement For Cell Therapies? CellProthera's CEO Thinks Not
- Closing The MES Value Gap: Why Technology Isn't The Problem
- Prevascularized Bio-hybrid Organ Platforms Are Redefining Cell Therapy Delivery
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
![GettyImages-2200128716-software-ai-machine-learning-percentages-code]( "Building Digital Capabilities For An Intelligent Tomorrow")
Building Digital Capabilities For An Intelligent TomorrowExplore how modern manufacturing software is transforming operations with AI-driven insights to empower CDMOs and CMOs to boost efficiency, agility, and client satisfaction in a competitive landscape.
-
![GettyImages-172799816 stem cells, blood collection]( "Cell Collection Basics For The Transplant And CGT Industries")
Cell Collection Basics For The Transplant And CGT IndustriesBreakthroughs in CAR T-cell and stem cell therapies depend on mastering cellular collection. Understanding these fundamentals is vital for advancing treatment efficacy and patient outcomes.
-
![GettyImages-157697835 lab, titer, research]( "Metabolic Phenotype Preservation And Suitability Of hMSCs Cultivated In Stirred Tank Bioreactors")
Metabolic Phenotype Preservation And Suitability Of hMSCs Cultivated In Stirred Tank BioreactorsLearn how researchers demonstrated scalable hADSC expansion in stirred-tank bioreactors using microcarriers, achieving metabolic stability and consistent growth for cell therapy applications.
-
![GettyImages-506999858-scientists-cell-culture-lab-development]( "Optimization And Scale-Up Of A Plasmid DNA Production Process")
Optimization And Scale-Up Of A Plasmid DNA Production ProcessOptimizing pDNA production in E. coli requires strategic media selection and scale-up planning. Explore a study that identifies ideal conditions for high-yield manufacturing.
-
![GettyImages-1382353763-hand-bubble-co2-green]( "Bio-Based Polymers Towards Net Zero In Single-Use Bioprocessing")
Bio-Based Polymers Towards Net Zero In Single-Use BioprocessingDecarbonizing healthcare and pharmaceuticals is vital to meet climate goals and safeguard public health. Learn why these energy-intensive sectors must act swiftly to reduce emissions and navigate complex global supply chains.
-
![GettyImages-576919878-analytics-computer-testing-research-data]( "Advancing An Integrated Biopharma Workflow Strategy")
Advancing An Integrated Biopharma Workflow StrategyGlobal research teams were generating critical data in disconnected systems, hindering collaboration. Explore how unified workflows and a shared data backbone strengthen efficiency.
-
![KingFisher Flex purification system]( "High-Performance Extraction And Quantitation Of Host-Cell Residual DNA")
High-Performance Extraction And Quantitation Of Host-Cell Residual DNAThis study presents a high-efficiency method for extracting and quantifying residual DNA from host cells using a semi-automated, high-throughput workflow.
-
![cell-therapy-GettyImages-1494029118]( "Sensitive Viral Safety Testing For Adventitious Virus Detection")
Sensitive Viral Safety Testing For Adventitious Virus DetectionDiscover a modern approach to adventitious virus detection that shows how targeted sequencing can achieve sensitive, comprehensive viral safety testing aligned with ICH MAP, RAP, and HAP expectations.
-
![GettyImages-2148428939-computer-business-woman-office]( "Why RWD Strategy Can't Wait With Price, Value And Evidence Pressures Everywhere")
Why RWD Strategy Can't Wait With Price, Value And Evidence Pressures EverywhereOvercome pricing pressures and reimbursement delays by integrating real-world evidence early in development to align clinical outcomes with payer demands and accelerate patient access.
-
![GettyImages-673804426 aseptic biologics clean room lab]( "Solve ATMP Aseptic Filling Challenges With Gloveless Isolators")
Solve ATMP Aseptic Filling Challenges With Gloveless IsolatorsHuman intervention is the top contamination risk in ATMP manufacturing. Robotic gloveless isolators address that risk through full automation and real-time monitoring during aseptic filling.
NEWSLETTER ARCHIVE
- 05.21.26 -- Advancing Bioprocessing: Perfusion And Process Intensification Across Modalities
- 05.21.26 -- Regeneron Advances In Vivo Gene Therapy For Hearing Loss
- 05.20.26 -- Streamlined Lentiviral Characterization And QC With Digital PCR
- 05.20.26 -- Tackling The Cell & Gene Therapy Sector's Practical Post-Approval Problem
- 05.19.26 -- Building Integrated cGMP Systems For Autologous Cell Therapies With MassGen's Tatyana Matveeva, Ph.D.
- CGT Manufacturing Shifts From Capacity To Strategy
- Dr. Peter Marks On Why Gene Therapy May Need A New Regulatory Playbook
- Regeneron Advances In Vivo Gene Therapy For Hearing Loss
- Sana, Mayo Clinic Advance A New Model For Cell Therapy Delivery In T1D
- Reprogramming T-Cell Access To Solid Tumors Through Improved Trafficking And Entry
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections
